Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to acquire a 100% stake in Guizhou Hengba Pharmaceutical Co., Ltd, a traditional Chinese medicine (TCM) firm, for a total consideration of RMB 528.47 million (USD 72.66 million). Established in 1995, Hengba Pharmaceutical has a robust portfolio of 21 TCM approvals and 2 chemical drug approvals. The company also has an impressive presence in the National Reimbursement Drug List (NRDL), with 4 Category A listings and 10 Category B listings, indicating its strong market position and the wide acceptance of its products.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
